QT Myopia and Cardiac Safety: Expanding the Aperture of Arrhythmia Assessment in Early Phase Drug Development [0.03%]
QT近视与心脏安全性：早期药物开发中扩大心律失常评估的视野
Robert M Lester,Katherine Clark,Sabina Paglialunga
Robert M Lester
Regulatory agencies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, and the Japanese Pharmaceutical and Medical Device Agency (PMDA) provide scientific and public health guidance with cardiac ...
Is Fel d1 Based Component Resolved Diagnosis Associated With Airway Inflammation in Cat Sensitized Children? [0.03%]
基于Fel d1成分的诊断与猫过敏儿童气道炎症有关吗？
Gökhan Kaya,Hasan Yüksel,Fatma Taneli et al.
Gökhan Kaya et al.
In cat sensitized children, decision to eliminate exposure to cats depends on the clinical outcome. In this study, we aimed to examine the relationship between molecular cat allergen sensitization and exhaled breath condensate (EBC) IL-4, I...
Clinician Satisfaction With Pharmacogenomics Clinical Services at a Multistate Health System [0.03%]
一个多州医疗系统中临床医生对药物基因组学临床服务的满意度
Kristen Jacobsen,Natasha J Petry,Max Weaver et al.
Kristen Jacobsen et al.
Pharmacogenomics (PGx) utilizes genetic information to optimize medication management. Barriers to PGx implementation include limited confidence and knowledge in applying results, time constraints, and financial barriers. Clinical services ...
Diabetes Knowledge and Medication Adherence Among High-Risk Type 2 Diabetic Patients in a Rural Area in Vietnam: A Cross-Sectional Study [0.03%]
越南农村地区高风险2型糖尿病患者糖尿病知识与用药依从性横断面研究
Huong Thi Thu Ho,Ha Thi Vo,Pramote Tragulpiankit et al.
Huong Thi Thu Ho et al.
Type 2 diabetes mellitus (T2DM) is becoming increasingly prevalent worldwide, especially in developing countries such as Vietnam; however, data on diabetes knowledge and medication adherence among Vietnamese high-risk T2DM patients, particu...
Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC [0.03%]
现有方法回顾及药物计量学在晚期非小细胞肺癌预后循环血清生物标志物解读中的潜在作用的评述
Francis Williams Ojara,Yomna M Nassar,Kimberly Geiger et al.
Francis Williams Ojara et al.
Circulating serum biomarkers have prognostic value in patients with advanced NSCLC, yet their potential still remains underappreciated at present. This review discusses classical approaches of biomarker data analysis, highlighting gaps, and...
Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor [0.03%]
Ocadusertib的选择性相互作用受体丝裂原活化蛋白激酶1抑制剂的早期开发
Simon J Shaw,Vanessa C Taylor,Jonathan T Sims et al.
Simon J Shaw et al.
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors are being investigated for chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib is a potent and selectiv...
Clinical Trial
Clinical and translational science. 2026 Mar;19(3):e70519. DOI:10.1111/cts.70519 2026
Neha Maharao,Donghong Xu,Punag Divanji et al.
Neha Maharao et al.
Aficamten is a next-in-class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A compr...
Clinical Trial
Clinical and translational science. 2026 Mar;19(3):e70514. DOI:10.1111/cts.70514 2026
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib and Effect on the QT/QTc Interval in Healthy Participants [0.03%]
评价Fenebrutinib在健康受试者中的安全性、耐受性和药代动力学以及对QT/QTc间期影响的I期研究
Yan Xu,Sonoko Kawakatsu,Denison Kuruvilla et al.
Yan Xu et al.
Fenebrutinib is a Bruton's tyrosine kinase inhibitor under investigation for the treatment of multiple sclerosis. The goal of this study was to investigate the effect of fenebrutinib on cardiac repolarization (QT interval) as well as its sa...
Clinical Trial
Clinical and translational science. 2026 Mar;19(3):e70518. DOI:10.1111/cts.70518 2026
Evaluation of the Effect of Food and Formulation on the Pharmacokinetics of the SHP2 Inhibitor Migoprotafib Within a Phase I Study in Cancer Patients [0.03%]
一项在癌症患者中进行的研究：评估食物和配方对SHP2抑制剂米加普罗他菲药代动力学影响的评价
Julia Suchomel,Christine M Bowman,Po-Chang Chiang et al.
Julia Suchomel et al.
Migoprotafib is a potent and selective inhibitor of Src homology-2 domain-containing phosphatase 2 (SHP2) under investigation in Phase I (PhI) trials both as monotherapy and in combination with multiple therapies for patients with metastati...
Clinical Trial
Clinical and translational science. 2026 Mar;19(3):e70512. DOI:10.1111/cts.70512 2026
Managing High-Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice Service [0.03%]
奈玛特瑞韦/利托那韦高危药物相互作用的管理——来自药理学咨询服务中心的经验
Youssef Libiad,Bénédicte Franck,Camille Tron et al.
Youssef Libiad et al.
Nirmatrelvir boosted with ritonavir is a key antiviral against COVID-19, yet ritonavir's potent CYP3A4 inhibition exposes patients to numerous drug-drug interactions. To make prescribing safer, a national proactive system providing expert p...